今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

官方下场最可怕，苹果iOS 18 今年又要“逼死”一批第三方应用

北京，2024年6月14日 - 据悉，苹果将于今年秋季发布iOS 18新系统，而此次更新将带来一系列重磅功能，其中一些功能可能会对第三方应用造成重大冲击，甚至让一些应用无路可走。

锁屏功能再升级，第三方应用地位堪忧

iOS 18将对锁屏功能进行重大升级，允许用户在锁屏界面直接添加小组件和进行更多操作，这对于第三方应用来说无疑是个坏消息。此前，锁屏界面一直是苹果原生应用的专属领地，第三方应用只能通过通知栏的方式触达用户。而现在，随着锁屏功能的开放，第三方应用将面临着来自苹果原生应用的直接竞争。

支付功能再整合，第三方支付或将式微

iOS 18还将进一步整合支付功能，将“Apple Pay Later”纳入“钱包”应用，并允许用户直接在App Store中使用“Apple Pay Later”进行分期付款。这对于第三方支付平台来说无疑是一个巨大的挑战。此前，第三方支付平台一直是用户在App Store中进行支付的主要方式之一。而现在，随着“Apple Pay Later”的普及，第三方支付平台的市场份额可能会受到大幅挤压。

健康数据加强管控，第三方应用难以为继

iOS 18还将加强对用户健康数据的管控，允许用户更加轻松地管理自己的健康数据。这对于第三方健康应用来说也是一个严峻的挑战。此前，许多第三方健康应用都依靠收集用户健康数据来提供服务。而现在，随着用户健康数据隐私意识的增强，以及苹果对健康数据的加强管控，第三方健康应用将很难再获取到足够的用户数据，从而难以维持正常运营。

结语

总而言之，苹果iOS 18的发布将会对第三方应用生态造成重大影响。一些功能可能会对第三方应用造成直接冲击，甚至让一些应用无路可走。第三方应用开发者需要密切关注iOS 18的更新情况，并及时调整自己的策略，以应对苹果的挑战。

以下是一些建议，可以帮助第三方应用开发者应对苹果iOS 18带来的挑战:

• 关注iOS 18的新功能和变化，及时调整自己的应用以适应新系统。
• 提高应用的竞争力，提供更加优质的服务和体验，以吸引用户。
• 加强用户隐私数据的保护，赢得用户的信任。
• 积极与苹果合作，寻求共赢之道。